Compare BioNTech SE - ADR (BNTX) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Marriott International Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Marriott International Inc trades at $362.11 (market cap $95.77B). The key difference: Marriott International Inc is far larger — about 4.2× BioNTech SE - ADR's market cap, and Marriott International Inc pays a 0.8% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MAR | |
|---|---|---|
Market Cap | $22.86B | $95.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $402.54 |
52-Week Low | $83.89 | $255.35 |
Enterprise Value | $6.53B | $112.72B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Marriott International (MAR) trades at $362.87, down 3.52% today, with a bearish technical signal and mixed earnings history. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Recent developments include the launch of Ask Bonvoy AI and expansion to 10,000 properties, though debt levels have risen to 58.83% of assets. Analyst consensus is a $387.33 price target with 44% buy ratings.
The outlook is cautiously optimistic given solid fundamentals and strategic initiatives, but high valuation ratios and increasing leverage pose risks. Near-term performance hinges on Q2 2026 earnings due August 3, 2026, with investor focus on debt management and travel demand sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
